Titan Pharmaceuticals Inc
NASDAQ:TTNP
Titan Pharmaceuticals Inc
NASDAQ:TTNP
Price:
4.61
USD
Market Cap:
$6.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Titan Pharmaceuticals Inc
NASDAQ:TTNP
|
US |
|
Magna Terra Minerals Inc
XTSX:MTT
|
CA |
|
Emkay Global Financial Services Ltd
NSE:EMKAY
|
IN |
|
Kexing Biopharm Co Ltd
SSE:688136
|
CN |
|
Voltalia SA
PAR:VLTSA
|
FR |
|
AFC Energy PLC
LSE:AFC
|
UK |
|
P
|
PayPal Holdings Inc
F:2PP
|
US |
|
W
|
WAG Payment Solutions PLC
LSE:WPS
|
UK |
|
First Mid Bancshares Inc
NASDAQ:FMBH
|
US |
|
Walchandnagar Industries Ltd
NSE:WALCHANNAG
|
IN |
|
S
|
SA Corporate Real Estate Fund Managers (Pty) Ltd
JSE:SAC
|
ZA |
|
S
|
Square Enix Holdings Co Ltd
SWB:EI4
|
JP |
|
T
|
Telefield Inc
KOSDAQ:091440
|
KR |
|
Avenir Telecom SA
PAR:AVT
|
FR |
|
D
|
Daphne International Holdings Ltd
F:PSX
|
CN |
|
C
|
CHTC Fong's International Co Ltd
HKEX:641
|
HK |
|
Latin Metals Inc
XTSX:LMS
|
CA |
|
Orpea SA
OTC:ORPEF
|
FR |
Multiples-Based Value
The
Multiples-Based Value for
Titan Pharmaceuticals Inc (TTNP)
under the Base Case is
hidden
USD.
Compared with the current market price of 4.61 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TTNP Multiples-Based Value
LOCKED
Multiples Across Competitors
TTNP Competitors Multiples
Titan Pharmaceuticals Inc Competitors
Titan Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Titan Pharmaceuticals Inc
NASDAQ:TTNP
|
6.1m USD | 0 | -1.3 | -0.7 | -0.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.4 | 42.4 | 28.6 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.6 | 15 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.5 | 20.4 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
